Inovio and VGX Pharma Merge


San Diego DNA vaccine developer Inovio Biomedical (NYSE: INO) says it has completed its merger with VGX Pharmaceuticals of Blue Bell, PA. The combination gives Inovio more time to develop its approach to new preventive and therapeutic vaccines against cancers and chronic infectious diseases such as HIV. Inovio says it has $11.7 million in available cash and VGX had $2.7 million, as of the end of March.  Inovio says this cash position will support Inovio’s operations through Q2 2010.

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at or call (619) 669-8788 Follow @

By posting a comment, you agree to our terms and conditions.